Maxwell Skor
Stock Analyst at Morgan Stanley
(2.91)
# 1,693
Out of 5,090 analysts
7
Total ratings
66.67%
Success rate
42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Initiates: Overweight | $190 | $220.36 | -13.78% | 1 | Oct 16, 2025 | |
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $204.00 | -29.41% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $205.44 | +21.69% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $5.13 | +133.92% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.08 | +825.93% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $2.23 | +59.19% | 2 | Nov 20, 2024 |
Cidara Therapeutics
Oct 16, 2025
Initiates: Overweight
Price Target: $190
Current: $220.36
Upside: -13.78%
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $204.00
Upside: -29.41%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $205.44
Upside: +21.69%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $5.13
Upside: +133.92%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.08
Upside: +825.93%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $2.23
Upside: +59.19%